Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates

Pharmacology Biochemistry and Behavior

Volumn 96, Issue 3, 2010, Pages 274-278

  Czoty, Paul W ^a   Martelle, Jennifer L ^a   Carroll, F Ivy ^b   Nader, Michael A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Agonist medication; Cocaine; Dopamine; Dopamine transporter; Nonhuman primates; Progressive ratio schedule; Self administration

Indexed keywords

3BETA (4 CHLOROPHENYL) 2BETA [3 (4' METHYLPHENYL)ISOXAZOL 5 YL]TROPANE; 3BETA (4 CHLOROPHENYL) 2BETA [3 PHENYLISOXAZOL 5 YL]TROPANE; COCAINE; COCAINE DERIVATIVE; UNCLASSIFIED DRUG; 3-(4'-CHLOROPHENYL)-2-(3'-PHENYLISOXAZOL-5'-YL)TROPANE; 3BETA-(4-CHLOROPHENYL) TROPANE-2BETA-(3-(4'-METHYLPHENYL) ISOXAZOL-5-YL) HYDROCHLORIDE; DOPAMINE UPTAKE INHIBITOR; TROPANE DERIVATIVE; WF 11;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; MALE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; RHESUS MONKEY; ANIMAL; COCAINE DEPENDENCE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG SELF ADMINISTRATION; INSTRUMENTAL CONDITIONING; PSYCHOLOGY;

ANIMALS; COCAINE; COCAINE-RELATED DISORDERS; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MACACA MULATTA; MALE; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; TROPANES;

MACACA MULATTA; PRIMATES;

EID: 77954757482     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.05.017     Document Type: Article

References (40)

1. Arnold J.M., Roberts D.C.S. A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 1997, 57:441-447.
2. Bergman J., Madras B.K., Johnson S.E., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 1989, 251:150-155.
3. Birmingham A.M., Nader S.H., Grant K.A., Davies H.M., Nader M.A. Further evaluation of the reinforcing effects of the novel cocaine analog 2β-propanoyl-3β-(4-tolyl)-tropane (PTT) in rhesus monkeys. Psychopharmacology 1998, 136:139-147.
4. Carroll F.I. Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy. J Med Chem 2003, 46:1775-1794.
5. Carroll F.I., Howell L.L., Kuhar M.J. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 1999, 42:2721-2736.
6. Carroll F.I., Pawlush N., Kuhar M.J., Pollard G.T., Howard J.L. Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3'-substituted isoxazol-5-yl)tropanes. J Med Chem 2004, 47:296-302.
7. Carroll F.I., Runyon S.P., Abraham P., Navarro H., Kuhar M.J., Pollard G.T., et al. Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers. J Med Chem 2004, 47:6401-6409.
8. Carroll F.I., Fox B.S., Kuhar M.J., Howard J.L., Pollard G.T., Schenk S. Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration. Eur J Pharmacol 2006, 553:149-156.
9. Carroll F.I., Howard J.L., Howell L.L., Fox B.S., Kuhar M.J. Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J 2006, 8:E196-E203.
10. Grabowski J., Shearer J., Merrill J., Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 2004, 29:1439-1464.
11. Haile C.N., Zhang X.Y., Carroll F.I., Kosten T.A. Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI-336, a 3-phenyltropane analog that binds to the dopamine transporter. Brain Res 2005, 1055:186-195.
12. Howell L.L., Wilcox K.M. The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther 2001, 298:1-6.
13. Howell L.L., Carroll F.I., Votaw J.R., Goodman M.M., Kimmel H.L. Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 2007, 320:757-765.
14. Katz J.L. Models of relative reinforcing efficacy of drugs and their predictive utility. Behav Pharmacol 1990, 1:283-301.
15. Kimmel H.L., Carroll F.I., Kuhar M.J. Locomotor stimulant effects of novel phenyltropanes in the mouse. Drug Alcohol Depend 2001, 65:25-36.
16. Kimmel H.L., O'Connor J.A., Carroll F.I., Howell L.L. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol Biochem Behav 2007, 86:45-54.
17. Kimmel H.L., Negus S.S., Wilcox K.M., Ewing S.B., Stehouwer J., Goodman M.M., et al. Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav 2008, 90:453-462.
18. Kuhar M.J., McGirr K.M., Hunter R.G., Lambert P.D., Garrett B.E., Carroll F.I. Studies of selected phenyltropanes at monoamine transporters. Drug Alcohol Depend 1999, 56:9-15.
19. Lile J.A., Nader M.A. The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models. Curr Neuropharmacol 2003, 1:21-46.
20. Lile J.A., Morgan D., Freedland C.S., Sinnott R.S., Davies H.M., Nader M.A. Self-administration of two long-acting monoamine transport blockers in rhesus monkeys. Psychopharmacology 2000, 152:414-421.
21. Lile J.A., Morgan D., Birmingham A.M., Wang Z., Woolverton W.L., Davies H.M., et al. The reinforcing efficacy of the dopamine reuptake inhibitor 2β-propanoyl-3β-(4-tolyl)-tropane (PTT) as measured by a progressive-ratio schedule and a choice procedure in rhesus monkeys. J Pharmacol Exp Ther 2002, 303:640-648.
22. Lile J.A., Wang Z., Woolverton W.L., France J.E., Gregg T.C., Davies H.M., et al. The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. J Pharmacol Exp Ther 2003, 307:356-366.
23. Lindsey K.P., Wilcox K.M., Votaw J.R., Goodman M.M., Plisson C., Carroll F.I., et al. Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther 2004, 309:959-969.
24. Martelle J.M., Czoty P.W., Nader M.A. Effect of time-out duration on the reinforcing strength of cocaine assessed under a progressive-ratio schedule in rhesus monkeys. Behav Pharmacol 2008, 19:743-746.
25. Mello N.K., Negus S.S. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 1996, 14:375-424.
26. Nader M.A., Grant K.A., Davies H.M., Mach R.H., Childers S.R. The reinforcing and discriminative stimulus effects of the novel cocaine analog 2β-propanoyl-3β-(4-tolyl)-tropane in rhesus monkeys. J Pharmacol Exp Ther 1997, 280:541-550.
27. Platt D.M., Rowlett J.K., Spealman R.D. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 2002, 163:265-282.
28. Richardson N.R., Roberts D.C. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 1996, 66:1-11.
29. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237:1219-1223.
30. Rothman R.B., Glowa J.R. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development: focus on GBR 12909. Mol Neurobiol 1995, 10:1-19.
31. Rothman R.B., Blough B.E., Woolverton W.L., Anderson K.G., Negus S.S., Mello N.K., et al. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 2005, 313:1361-1369.
32. Rowlett J.K., Massey B.W., Kleven M.S., Woolverton W.L. Parametric analysis of cocaine self-administration under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology 1996, 125:361-370.
33. Stafford D., LeSage M.G., Rice K.C., Glowa J.R. A comparison of cocaine, GBR 12909, and phentermine self-administration by rhesus monkeys on a progressive-ratio schedule. Drug Alcohol Depend 2001, 62:41-47.
34. Stathis M., Scheffel U., Lever S.Z., Boja J.W., Carroll F.I., Kuhar M.J. Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology 1995, 119:376-384.
35. Vocci F.J., Acri J., Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005, 162:1432-1440.
36. Volkow N.D., Fowler J.S., Wang G.J. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 1999, 13:337-345.
37. Volkow N.D., Wang G.J., Fischman M.W., Foltin R., Fowler J.S., Franceschi D., et al. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci 2000, 67:1507-1515.
38. Volkow N.D., Fowler J.S., Wang G.J., Ding Y.S., Gatley S.J. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 2002, 12:557-566.
39. Woolverton W.L., Ranaldi R., Wang Z., Ordway G.A., Paul I.A., Petukhov P., et al. Reinforcing strength of a novel dopamine transporter ligand: pharmacodynamic and pharmacokinetic mechanisms. J Pharmacol Exp Ther 2002, 303:211-217.
40. Woolverton W.L., Wang Z. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol 2004, 486:251-257.